Switch theme
Sign up to access all valuation multiples
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
2002
110
LTM Revenue $3.8M
LTM EBITDA -$147M
$225M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
DBV Technologies has a last 12-month revenue (LTM) of $3.8M and a last 12-month EBITDA of -$147M.
In the most recent fiscal year, DBV Technologies achieved revenue of n/a and an EBITDA of -$122M.
DBV Technologies expects next 12-month revenue of XXX and NTM EBITDA of XXX
See DBV Technologies valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.8M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $3.8M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$147M | XXX | -$122M | XXX | XXX | XXX |
| EBITDA Margin | -3885% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$126M | XXX | -$131M | XXX | XXX | XXX |
| EBIT Margin | -3323% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$129M | XXX | -$128M | XXX | XXX | XXX |
| Net Margin | -3405% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, DBV Technologies's stock price is EUR 1 (or $2).
DBV Technologies has current market cap of EUR 205M (or $230M), and EV of EUR 200M (or $225M).
See DBV Technologies trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $225M | $230M | XXX | XXX | XXX | XXX | $-0.40 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, DBV Technologies has market cap of $230M and EV of $225M.
DBV Technologies's trades at n/a EV/Revenue multiple, and -1.8x EV/EBITDA.
Equity research analysts estimate DBV Technologies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
DBV Technologies has a P/E ratio of -1.8x.
See valuation multiples for DBV Technologies and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $230M | XXX | $230M | XXX | XXX | XXX |
| EV (current) | $225M | XXX | $225M | XXX | XXX | XXX |
| EV/Revenue | 59.5x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -1.5x | XXX | -1.8x | XXX | XXX | XXX |
| EV/EBIT | -1.8x | XXX | -1.7x | XXX | XXX | XXX |
| EV/Gross Profit | 59.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.8x | XXX | -1.8x | XXX | XXX | XXX |
| EV/FCF | -1.8x | XXX | -1.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDBV Technologies's last 12 month revenue growth is 182%
DBV Technologies's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.2M for the same period.
DBV Technologies's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
DBV Technologies's rule of X is -3430% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for DBV Technologies and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 182% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -3885% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -3430% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| LTR Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Starpharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Schott Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanoform | XXX | XXX | XXX | XXX | XXX | XXX |
| Peptron | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
DBV Technologies acquired XXX companies to date.
Last acquisition by DBV Technologies was XXXXXXXX, XXXXX XXXXX XXXXXX . DBV Technologies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was DBV Technologies founded? | DBV Technologies was founded in 2002. |
| Where is DBV Technologies headquartered? | DBV Technologies is headquartered in France. |
| How many employees does DBV Technologies have? | As of today, DBV Technologies has 110 employees. |
| Who is the CEO of DBV Technologies? | DBV Technologies's CEO is Mr. Daniel Tasse. |
| Is DBV Technologies publicy listed? | Yes, DBV Technologies is a public company listed on PAR. |
| What is the stock symbol of DBV Technologies? | DBV Technologies trades under DBV ticker. |
| When did DBV Technologies go public? | DBV Technologies went public in 2012. |
| Who are competitors of DBV Technologies? | Similar companies to DBV Technologies include e.g. LTR Pharma, Starpharma, Schott Pharma, Nanoform. |
| What is the current market cap of DBV Technologies? | DBV Technologies's current market cap is $230M |
| What is the current revenue of DBV Technologies? | DBV Technologies's last 12 months revenue is $3.8M. |
| What is the current revenue growth of DBV Technologies? | DBV Technologies revenue growth (NTM/LTM) is 182%. |
| What is the current EV/Revenue multiple of DBV Technologies? | Current revenue multiple of DBV Technologies is 59.5x. |
| Is DBV Technologies profitable? | Yes, DBV Technologies is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of DBV Technologies? | DBV Technologies's last 12 months EBITDA is -$147M. |
| What is DBV Technologies's EBITDA margin? | DBV Technologies's last 12 months EBITDA margin is -3885%. |
| What is the current EV/EBITDA multiple of DBV Technologies? | Current EBITDA multiple of DBV Technologies is -1.5x. |
| What is the current FCF of DBV Technologies? | DBV Technologies's last 12 months FCF is -$126M. |
| What is DBV Technologies's FCF margin? | DBV Technologies's last 12 months FCF margin is -3328%. |
| What is the current EV/FCF multiple of DBV Technologies? | Current FCF multiple of DBV Technologies is -1.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
